Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations

PHASE1UnknownINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

January 31, 2019

Conditions
Mild Cognitive ImpairmentAlzheimer's Disease
Interventions
DEVICE

Sapphire II

A Class 1 laser device used in conjunction with the ointment to measure fluorescence emissions from the anterior segment (lens) of the eye.

DRUG

Aftobetin-HCl

The medical imaging agent (the ointment), Aftobetin-HCl is an amyloid binding ligand formulated into an ophthalmic ointment.

RADIATION

Positron Emission Tomography

Amyvid 370 MBq (10 mCi) is administered as a single bolus through a short intravenous catheter in a total volume of 10 mL.

Trial Locations (1)

33407

RECRUITING

Neurology Research Institute, West Palm Beach

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cognoptix, Inc.

INDUSTRY